Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001144808
Ethics application status
Approved
Date submitted
21/09/2012
Date registered
30/10/2012
Date last updated
4/09/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Can uraemic symptoms be reduced by changing the saliva environment in chronic kidney disease
Scientific title
Can uraemic symptoms be reduced by changing the saliva environment in chronic kidney disease?
Secondary ID [1] 281455 0
'Nil'
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Uraemia 287367 0
Malnutrition 287368 0
Chronic kidney disease 287487 0
Condition category
Condition code
Renal and Urogenital 287697 287697 0 0
Kidney disease
Diet and Nutrition 287818 287818 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Trial mouthrinses of various solutions of common oral fluids to see what impoves taste and symptoms of uraemia
Salt 5g dissolved in 500ml cold water
Sodium bicarbonate 5g dissolved in 500ml cold water
Citric acid 1g dissolved in 500mlcold water
500ml de-ionised water
Sip and spit as required
Random sequence 1 each day.
Questionaire re tolerance and symptom.
Intervention code [1] 285650 0
Treatment: Other
Comparator / control treatment
4 solutions were trialled
Salt 5g dissolved in 500ml cold water
Sodium bicarbonate 5g dissolved in 500ml cold water
Citric acid 1g dissolved in 500mlcold water
500ml de-ionised water
Control group
Active

Outcomes
Primary outcome [1] 287945 0
Improved uraemic symptoms using PG-SGA, and a specific symptom questionaire designed for the study.
Timepoint [1] 287945 0
Day 0,1,2,3,4,5,6,7, and 30
Secondary outcome [1] 299102 0
Improved nutritional intake using 24 hour food recall
Timepoint [1] 299102 0
Day 1 and 30

Eligibility
Key inclusion criteria
chronic kidney disease patients with uraemic symptoms
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unwilling or unable to sign consent form

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All renal patients screened by PG-SGA with gastric uraemic symptoms will be asked to participate. Allocation not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computerised sequence generation.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Crossover. All the participatants receive all the interventions in different sequences during the study acting as their own control. On selection of the solution that improves that patient's symptoms the most, the solution code will be revealed and the patient will continue using this solution as needed from day eight to day 30.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/03/2013
Actual
3/06/2013
Date of last participant enrolment
Anticipated
29/04/2014
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
42
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 285968 0
Charities/Societies/Foundations
Name [1] 285968 0
Dialysis And Transplant Association
Country [1] 285968 0
Australia
Funding source category [2] 286225 0
Hospital
Name [2] 286225 0
Austin Medical Research Foundation
Country [2] 286225 0
Australia
Primary sponsor type
Hospital
Name
Austin Health
Address
145 Studley Rd
Heidelberg
Vic 3084
Country
Australia
Secondary sponsor category [1] 284792 0
None
Name [1] 284792 0
Address [1] 284792 0
Country [1] 284792 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288000 0
Austin Health Human Ethic Research Committee
Ethics committee address [1] 288000 0
Ethics committee country [1] 288000 0
Australia
Date submitted for ethics approval [1] 288000 0
01/12/2012
Approval date [1] 288000 0
25/01/2013
Ethics approval number [1] 288000 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34687 0
Ms Karen Manley
Address 34687 0
Austin Health
145 Studley Rd
Heidelberg
Vic 3084
Country 34687 0
Australia
Phone 34687 0
61 3 94965646
Fax 34687 0
Email 34687 0
[email protected]
Contact person for public queries
Name 17934 0
Karen Manley
Address 17934 0
Austin Health
145 Studley Rd
Heidelberg
Vic 3084
Country 17934 0
Australia
Phone 17934 0
+61 03 94965646
Fax 17934 0
Email 17934 0
[email protected]
Contact person for scientific queries
Name 8862 0
Karen Manley
Address 8862 0
Austin Health
145 Studley Rd
Heidelberg
Vic 3084
Country 8862 0
Australia
Phone 8862 0
+61 3 94965646
Fax 8862 0
Email 8862 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.